Stem Cell-Based in Vitro Models: State-of-the-Art Tools to Predict Drug-Induced Tissue Injury in Humans
This record is part of
a dataset collected by the EU Commission in June-September 2018
. Some of these links will therefore die out with time.
Please see the
overview of courses maintained by ETPLAS
or contact Norecopa for more information.
Owner/Developer: The European Society of Toxicology In Vitro and The American Society for Cellular and Computational Toxicology (ESTIV, ASCCT)
| Country: |
Belgium |
|---|---|
| Languages: |
English |
| Url: |
https://register.gotowebinar.com/register/1379509253994847746 |
| Created: |
23 October 2018 |
| Format: |
Webinars |
| Presence: |
Optional / Voluntary |
| Access: |
Free |
| Content type: |
Theoretical |
| Duration: |
1 h |
| Target audience: |
Students, Researchers, Regulators and policy-makers, Teachers and educators, Technicians, Managers, Scientific officers / Project managers, Professionals (e.g. veterinarians), General public |
| Target sectors: |
Academia, Industry, Governmental bodies, Contract Research Organizations (CROs), Consulting, SMEs |
| Educational level: |
University (Bachelor), University (Master), University (Doctoral education), Postdoctoral (teaching and research), Continuing Professional Development |
| 3rs relevance: |
Replacement |
| Topics covered: |
In vitro methods |
| 3rs coverage: |
Full coverage (a dedicated course) |
| Details on the topic or technology covered: |
The fact that the detection of drug toxicity is often not accurate and frequently occurs only late during the drug development process is of major concern for the pharmaceutical industry and jeopardizes the potential marketing of new chemical entities. Besides affecting human health, this also leads to a significant loss of resources and time for the pharmaceutical industry. One of the major reasons for this failure is that the safety of new potential drugs is still evaluated in animals or animal-based cell lines. However, efforts at improving the predictability of drug-induced tissue injury in humans are rising due to the rapidly advancing field of human stem cell research. Human target cells for screening and assessment of adverse drug effects in humans can now be generated using pluripotent and multipotent stem cells as detailed in vitro differentiation protocols are established for almost all cell (sub) types. The introduction of state-of-the-art gene editing tools such as CRISPR/Cas9 in stem cell research provides a technology platform to mimic specific genetic polymorphisms or diseases in a dish. In addition, stem cell-based in vitro models can be used to evaluate adverse drug effects during the differentiation process thereby mimicking human developmental toxicity. The latter provides a major advantage over any other non- stem cell-based model. Ultimately, it will be possible to develop personalized toxicology to determine inter-individual susceptibility to adverse drug reactions at any stage of development and in health and disease. |
Fant du det du lette etter?
Ja, jeg fant det! Nei, jeg fant det ikke!Takk for din tilbakemelding! Vær oppmerksom på at vi ikke kan kontakte deg hvis ikke du oppgir din epostadresse.
Hva lette du etter?
Gi oss gjerne en tilbakemelding slik at vi kan forbedre informasjonen på siden. På forhånd takk for hjelpen! Vennligst skriv inn din epostadresse hvis du vil ha et svar.
Kontakt oss gjerne på e-post hvis du har spørsmål.